{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T20:19:15Z","timestamp":1777493955207,"version":"3.51.4"},"reference-count":66,"publisher":"Walter de Gruyter GmbH","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,9,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n<jats:p>The efficacy of HIV-1 protease (PR) inhibition therapies is often compromised by the emergence of mutations in the PR molecule that reduces the binding affinity of inhibitors while maintaining viable catalytic activity and affinity for natural substrates. In the present study, we used a recombinant HIV-1 C-SA PR and a recently reported variant for inhibition (<jats:italic>K<\/jats:italic><jats:sub>i<\/jats:sub>, IC<jats:sub>50<\/jats:sub>) and thermodynamic studies against nine clinically used inhibitors. This is the first time that binding free energies for C-SA PR and the mutant are reported. This variant PR harbours a mutation and insertion (I36T\u2191T) at position 36 of the C-SA HIV-1 PR, and did not show a significant difference in the catalytic effect of the HIV-1 PR. However, the nine clinically approved HIV PR drugs used in this study demonstrated weaker inhibition and lower binding affinities toward the variant when compared to the wild type HIV-1 PR. All the protease inhibitors (PIs), except Amprenavir and Ritonavir exhibited a significant decrease in binding affinity (<jats:italic>p<\/jats:italic>&lt;0.0001). Darunavir and Nelfinavir exhibited the weakest binding affinity, 155- and 95-fold decreases respectively, toward the variant. Vitality values for the variant PR, against the seven selected PIs, confirm the impact of the mutation and insertion on the South African HIV-1 subtype C PR. This information has important clinical implications for thousands of patients in Sub-Saharan Africa.<\/jats:p>","DOI":"10.1515\/hsz-2017-0107","type":"journal-article","created":{"date-parts":[[2017,5,19]],"date-time":"2017-05-19T10:04:40Z","timestamp":1495188280000},"page":"1109-1117","source":"Crossref","is-referenced-by-count":13,"title":["I36T\u2191T mutation in South African subtype C (C-SA) HIV-1 protease significantly alters protease-drug interactions"],"prefix":"10.1515","volume":"398","author":[{"given":"Sibusiso B.","family":"Maseko","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eden","family":"Padayachee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2511-2503","authenticated-orcid":false,"given":"Thavendran","family":"Govender","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasien","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0606-2053","authenticated-orcid":false,"given":"Gert","family":"Kruger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9135-5370","authenticated-orcid":false,"given":"Glenn E.M.","family":"Maguire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9621-9343","authenticated-orcid":false,"given":"Johnson","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","reference":[{"key":"ref301","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1568005033481051","article-title":"Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design","volume":"3","year":"2003","journal-title":"Curr. Drug Targets Infect. Disord"},{"key":"ref401","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/bi00452a001","article-title":"Proteolytic processing of polyproteins in the replication of RNA viruses","volume":"28","year":"1989","journal-title":"Biochemistry"},{"key":"ref481","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cbdd.12690","article-title":"Binding free energy calculations of nine FDA\u2010approved protease inhibitors against HIV\u20101 subtype C I36T\u2191 T containing 100 amino acids per monomer","volume":"87","year":"2016","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref31","doi-asserted-by":"crossref","first-page":"12141","DOI":"10.1021\/bi049459m","article-title":"Comparing the accumulation of active-and nonactive-site mutations in the HIV-1 protease","volume":"43","year":"2004","journal-title":"Biochemistry"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"1243727","DOI":"10.1126\/science.1243727","article-title":"Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective","volume":"343","year":"2014","journal-title":"Science"},{"key":"ref291","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1074\/jbc.271.10.5458","article-title":"Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration","volume":"271","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref421","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1110\/ps.9.10.1898","article-title":"Crystal structure of an in vivo HIV\u20101 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance","volume":"9","year":"2000","journal-title":"Protein Sci."},{"key":"ref671","first-page":"2849","article-title":"Anti-HIV drug discovery and development: current innovations and future trends: miniperspective","volume":"59","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref551","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/JVI.02014-15","article-title":"A single maturation cleavage site in adenovirus impacts cell entry and capsid assembly","volume":"90","year":"2016","journal-title":"J. Virol."},{"key":"ref181","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/ja2095766","article-title":"Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease","volume":"134","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref581","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.biochem.6b00012","article-title":"Binding of clinical inhibitors to a model precursor of a rationally selected multidrug resistant HIV-1 protease is significantly weaker than that to the released mature enzyme","volume":"55","year":"2016","journal-title":"Biochemistry"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1073\/pnas.1400027111","article-title":"Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir","volume":"111","year":"2014","journal-title":"Proc. Nat. Acad. USA"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/cbdd.12690","article-title":"Binding free energy calculations of nine FDA\u2010approved protease inhibitors against HIV\u20101 subtype C I36T\u2191 T containing 100 amino acids per monomer","volume":"87","year":"2016","journal-title":"Chem. Biol. Drug. Des."},{"key":"ref441","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","year":"1988","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref111","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1135\/cccc20040703","article-title":"Characterisation of mutated proteinases derived from HIV-positive patients: enzyme activity, vitality and inhibition","volume":"69","year":"2004","journal-title":"Collect. Czech. Chem. Commun."},{"key":"ref631","doi-asserted-by":"crossref","first-page":"5458","DOI":"10.1074\/jbc.271.10.5458","article-title":"Conformational stability and catalytic activity of HIV-1 protease are both enhanced at high salt concentration","volume":"271","year":"1996","journal-title":"J. Biol. Chem."},{"key":"ref511","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pep.2016.02.013","article-title":"Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies","volume":"122","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"ref341","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular basis for drug resistance in HIV-1 protease","volume":"2","year":"2010","journal-title":"Viruses"},{"key":"ref431","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drudis.2006.12.011","article-title":"Targeting structural flexibility in HIV-1 protease inhibitor binding","volume":"12","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"9881","DOI":"10.1021\/bi00452a001","article-title":"Proteolytic processing of polyproteins in the replication of RNA viruses","volume":"28","year":"1989","journal-title":"Biochemistry"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1128\/JVI.00726-08","article-title":"Active site mutations in the South African HIV-1 subtype C protease impact significantly on clinical inhibitor binding: a kinetic and thermodynamic study","volume":"82","year":"2008","journal-title":"J. Virol."},{"key":"ref541","article-title":"Analyzing data with GraphPad prism Software Incorporated","author":"Motulsky","year":"1999"},{"key":"ref311","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","year":"2015","journal-title":"Topics Antiviral Med."},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1021\/ja076558p","article-title":"HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants","volume":"130","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref331","first-page":"2849","article-title":"Anti-HIV drug discovery and development: current innovations and future trends: miniperspective","volume":"59","year":"2015","journal-title":"J. Med. Chem."},{"key":"ref471","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/abio.2000.4501","article-title":"High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants","volume":"281","year":"2000","journal-title":"Anal. Biochem."},{"key":"ref91","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.drudis.2006.12.011","article-title":"Targeting structural flexibility in HIV-1 protease inhibitor binding","volume":"12","year":"2007","journal-title":"Drug Discov. Today"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jmb.2007.09.083","article-title":"Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants","volume":"374","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref461","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.jmb.2007.09.083","article-title":"Molecular analysis of the HIV-1 resistance development: enzymatic activities, crystal structures, and thermodynamics of nelfinavir-resistant HIV protease mutants","volume":"374","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref621","article-title":"HIV-1 genetic variability and clinical implications","year":"2013","journal-title":"ISRN Microbiol"},{"key":"ref371","doi-asserted-by":"crossref","first-page":"12141","DOI":"10.1021\/bi049459m","article-title":"Comparing the accumulation of active-and nonactive-site mutations in the HIV-1 protease","volume":"43","year":"2004","journal-title":"Biochemistry"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1021\/acs.biochem.6b00012","article-title":"Binding of clinical inhibitors to a model precursor of a rationally selected multidrug resistant HIV-1 protease is significantly weaker than that to the released mature enzyme","volume":"55","year":"2016","journal-title":"Biochemistry"},{"key":"ref571","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.npep.2013.08.001","article-title":"Etiology of Alzheimer\u2019s disease: kinetic, thermodynamic and fluorimetric analyses of interactions of pseudo A\u03b2-peptides with neuronal nitric oxide synthase","volume":"47","year":"2013","journal-title":"Neuropeptides"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1073\/pnas.85.13.4686","article-title":"Active human immunodeficiency virus protease is required for viral infectivity","volume":"85","year":"1988","journal-title":"Proc. Nat. Acad. Sci. USA"},{"key":"ref611","first-page":"162","article-title":"HIV protease inhibitors: their anti-HIV activity and potential role in treatment","volume":"6","year":"1993","journal-title":"JAIDS"},{"key":"ref201","article-title":"Analyzing data with GraphPad prism Software Incorporated","author":"Motulsky","year":"1999"},{"key":"ref271","first-page":"162","article-title":"HIV protease inhibitors: their anti-HIV activity and potential role in treatment","volume":"6","year":"1993","journal-title":"JAIDS"},{"key":"ref491","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/bi9802521","article-title":"Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis","volume":"37","year":"1998","journal-title":"Biochemistry"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pep.2016.02.013","article-title":"Purification and characterization of naturally occurring HIV-1 (South African subtype C) protease mutants from inclusion bodies","volume":"122","year":"2016","journal-title":"Protein Expr. Purif."},{"key":"ref221","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1128\/JVI.02706-06","article-title":"Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations","volume":"81","year":"2007","journal-title":"J. Virol."},{"key":"ref381","doi-asserted-by":"crossref","first-page":"1243727","DOI":"10.1126\/science.1243727","article-title":"Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective","volume":"343","year":"2014","journal-title":"Science"},{"key":"ref601","first-page":"203","article-title":"The triple threat of HIV-1 protease inhibitors","volume":"389","year":"2015","journal-title":"In: The Future of HIV-1 Therapeutics. Curr Top Microbiol Immunol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1006\/abio.2000.4501","article-title":"High-throughput screening of enzyme inhibitors: automatic determination of tight-binding inhibition constants","volume":"281","year":"2000","journal-title":"Anal. Biochem."},{"key":"ref81","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1110\/ps.9.10.1898","article-title":"Crystal structure of an in vivo HIV\u20101 protease mutant in complex with saquinavir: insights into the mechanisms of drug resistance","volume":"9","year":"2000","journal-title":"Protein Sci."},{"key":"ref231","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.npep.2013.08.001","article-title":"Etiology of Alzheimer\u2019s disease: kinetic, thermodynamic and fluorimetric analyses of interactions of pseudo A\u03b2-peptides with neuronal nitric oxide synthase","volume":"47","year":"2013","journal-title":"Neuropeptides"},{"key":"ref641","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1568005033481051","article-title":"Structural and thermodynamic basis of resistance to HIV-1 protease inhibition: implications for inhibitor design","volume":"3","year":"2003","journal-title":"Curr. Drug Targets Infect. Disord"},{"key":"ref661","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1128\/AAC.49.9.3825-3832.2005","article-title":"Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors","volume":"49","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref561","doi-asserted-by":"crossref","first-page":"5144","DOI":"10.1128\/JVI.02706-06","article-title":"Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations","volume":"81","year":"2007","journal-title":"J. Virol."},{"key":"ref591","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","year":"2004","journal-title":"J Comput Chem"},{"key":"ref151","doi-asserted-by":"crossref","first-page":"5791","DOI":"10.1021\/bi9802521","article-title":"Molecular basis of resistance to HIV-1 protease inhibition: a plausible hypothesis","volume":"37","year":"1998","journal-title":"Biochemistry"},{"key":"ref391","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.1073\/pnas.1400027111","article-title":"Dimerization of HIV-1 protease occurs through two steps relating to the mechanism of protease dimerization inhibition by darunavir","volume":"111","year":"2014","journal-title":"Proc. Nat. Acad. USA"},{"key":"ref321","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1128\/AAC.49.9.3825-3832.2005","article-title":"Molecular basis for increased susceptibility of isolates with atazanavir resistance-conferring substitution I50L to other protease inhibitors","volume":"49","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref521","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/ja2095766","article-title":"Hydrophobic core flexibility modulates enzyme activity in HIV-1 protease","volume":"134","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref411","first-page":"493","article-title":"Integrated approach to structure-based enzymatic drug design: molecular modeling, spectroscopy, and experimental bioactivity","volume":"114","year":"2013","journal-title":"Chem. Rev."},{"key":"ref01","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/v2112509","article-title":"Molecular basis for drug resistance in HIV-1 protease","volume":"2","year":"2010","journal-title":"Viruses"},{"key":"ref71","first-page":"493","article-title":"Integrated approach to structure-based enzymatic drug design: molecular modeling, spectroscopy, and experimental bioactivity","volume":"114","year":"2013","journal-title":"Chem. Rev."},{"key":"ref351","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1021\/ja076558p","article-title":"HIV-1 protease inhibitors from inverse design in the substrate envelope exhibit subnanomolar binding to drug-resistant variants","volume":"130","year":"2008","journal-title":"J. Am. Chem. Soc."},{"key":"ref211","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1128\/JVI.02014-15","article-title":"A single maturation cleavage site in adenovirus impacts cell entry and capsid assembly","volume":"90","year":"2016","journal-title":"J. Virol."},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","year":"2004","journal-title":"J Comput Chem"},{"key":"ref281","article-title":"HIV-1 genetic variability and clinical implications","year":"2013","journal-title":"ISRN Microbiol"},{"key":"ref451","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1135\/cccc20040703","article-title":"Characterisation of mutated proteinases derived from HIV-positive patients: enzyme activity, vitality and inhibition","volume":"69","year":"2004","journal-title":"Collect. Czech. Chem. Commun."},{"key":"ref361","doi-asserted-by":"crossref","first-page":"e0147571","DOI":"10.1371\/journal.pone.0147571","article-title":"Identification of immunogenic cytotoxic T lymphocyte epitopes containing drug resistance mutations in antiretroviral treatment-na\u00efve HIV-infected individuals","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"ref651","first-page":"132","article-title":"2015 update of the drug resistance mutations in HIV-1","volume":"23","year":"2015","journal-title":"Topics Antiviral Med."},{"key":"ref21","doi-asserted-by":"crossref","first-page":"e0147571","DOI":"10.1371\/journal.pone.0147571","article-title":"Identification of immunogenic cytotoxic T lymphocyte epitopes containing drug resistance mutations in antiretroviral treatment-na\u00efve HIV-infected individuals","volume":"11","year":"2016","journal-title":"PLoS One"},{"key":"ref261","first-page":"203","article-title":"The triple threat of HIV-1 protease inhibitors","volume":"389","year":"2015","journal-title":"In: The Future of HIV-1 Therapeutics. Curr Top Microbiol Immunol"},{"key":"ref531","doi-asserted-by":"crossref","first-page":"11476","DOI":"10.1128\/JVI.00726-08","article-title":"Active site mutations in the South African HIV-1 subtype C protease impact significantly on clinical inhibitor binding: a kinetic and thermodynamic study","volume":"82","year":"2008","journal-title":"J. Virol."}],"container-title":["Biological Chemistry"],"original-title":[],"link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/bchm.2017.398.issue-10\/hsz-2017-0107\/hsz-2017-0107.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.degruyter.com\/view\/j\/bchm.2017.398.issue-10\/hsz-2017-0107\/hsz-2017-0107.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T22:51:49Z","timestamp":1614466309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/hsz-2017-0107\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,26]]},"references-count":66,"journal-issue":{"issue":"10"},"URL":"https:\/\/doi.org\/10.1515\/hsz-2017-0107","relation":{},"ISSN":["1437-4315","1431-6730"],"issn-type":[{"value":"1437-4315","type":"electronic"},{"value":"1431-6730","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9,26]]}}}